RightEye
RightEye leverages proven scientific research and a patented cloud-based software platform to deliver any eye movement test or therapy.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | $1.0m | Debt | |
| Total Funding | 000k | ||
Related Content
RightEye, a health technology company established in 2012 by co-founders Adam Gross and Dr. Melissa Hunfalvay, has developed a system centered on eye-tracking technology to address vision and brain health. The company's genesis is tied to Dr. Hunfalvay's extensive background as a research scientist and her prior career as a professional squash player, which provided her with insights into the connection between vision and high performance. This foundation led to the creation of a platform designed to provide objective, data-driven insights into a range of health issues.
The core of RightEye's business is its eye-tracking system, which has received FDA clearance for recording, viewing, and analyzing eye movements to assess visual tracking disorders in patients. This system supports a variety of applications, including a non-invasive test to help clinicians identify early signs of Parkinson's disease by analyzing specific eye movement patterns. The platform is utilized by a diverse client base, including optometrists, hospitals, and professional sports teams, who use the technology for concussion detection, functional vision screening, and performance enhancement. The business model appears to be based on selling this integrated hardware and software system to healthcare providers and other organizations.
The RightEye system administers a series of brief, game-like tests that patients follow on a screen. The process takes approximately five minutes and generates a detailed report that visualizes eye movements and compares them to a database of normative data. This allows healthcare professionals to move beyond subjective observations to quantitative, measurable data for diagnosing and monitoring conditions affecting the brain and vision. The reports provide a clear basis for patient consultation and for tracking the effectiveness of prescribed therapies over time, representing a significant shift in how visual and neurological health can be assessed.
Keywords: eye-tracking technology, health technology, vision assessment, brain health, objective data, FDA cleared, visual tracking, Parkinson's test, concussion detection, functional vision